Medicare Weighing National Part B Coverage For ViiV’s HIV PrEP Apretude As ‘Preventive Service’
Executive Summary
Unusual national coverage determination for a prevention-only drug was opened in response to a formal request from ViiV for its long-acting injectable.
You may also be interested in...
Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
Donanemab In Medicare: Quick Reversal Of Alzheimer’s Coverage Limits Doubtful, Lilly Says
Lilly execs caution that even if FDA approves donanemab in 2023, no uptake of any significance is expected until 2024 and beyond. An accelerated approval would essentially preclude Medicare reimbursement, and a CMS policy change or more persuasive trial data could take some time.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.